Approval of biosimilars in indications for which they were not studied directly in phase 3 clinical trials relies on the extrapolation of indications, a concept that is scientifically justified but, nevertheless, has generated some concerns among clinicians. In the case of biosimilar infliximab CT-P13 (Inflectra, Remsima), some gastroenterologists have voiced a lack of confidence in the biosimilar for the treatment of inflammatory bowel disease, including Crohn disease (CD) and ulcerative colitis. Now, head-to-head study, published in The Lancet, has produced data that may help allay those worries.
Approval of biosimilars in indications for which they were not studied directly in phase 3 clinical trials relies on the extrapolation of indications, a concept that is scientifically justified but, nevertheless, has generated some concerns among clinicians. In the case of biosimilar infliximab CT-P13 (Inflectra, Remsima), some gastroenterologists have voiced a lack of confidence in the biosimilar for the treatment of inflammatory bowel disease, including Crohn disease (CD) and ulcerative colitis. Now, head-to-head study, published in The Lancet, has produced data that may help allay those worries.
Between 2014 and 2017, the randomized, multicenter, double-blind, phase 3 noninferiority PLANETCD study enrolled 220 patients with active CD who were naïve to biologic therapy. The patients were randomized to receive CT-P13 only (n = 56), CT-P13 followed by reference infliximab (n = 55), reference infliximab only (n = 54), or reference infliximab followed by CT-P13 (n = 55), with a switch taking place at week 30.
Patients received 5 mg/kg of their assigned infliximab treatment at weeks 0, 2, 6, followed by every 8 weeks up to week 54. The study’s primary end point was the proportion of patients with a decrease of 70 points or more in the Crohn’s Disease Activity Index (CADI-70) from baseline to week 6. The prespecified noninferiority margin was set at −20%.
The CDAI-70 response rates at week 6 were similar for the patients who began their treatment with CT-P13. Among those who either took CT-P13 only or began with CT-P13 and switched to reference infliximab, 69.4% achieved CDAI-70 (95% CI, 59.9%-77.8%). Among those who took reference infliximab only or began treatment with reference infliximab and then switched to CT-P13, 74.3% achieved CDAI-70 (95% CI, 65.1%-82.2%), for a difference of −4.9% (95% CI, −16.9% to 7.3%), which fell within the prespecified noninferiority margin.
Overall, 67% of patients of patients experienced at least 1 treatment-emergent adverse event (TEAE), with 64% of patients in the CT-P13-only group, 62% in the CT-P13 to infliximab switch group, 69% in the infliximab only group, and 73% in the infliximab to CT-P13 switch group experiencing a TEAE.
“This is the first head-to-head study demonstrating the equal efficacy of an anti-TNF [anti−tumor necrosis factor] biosimilar in inflammatory bowel disease,” said Stefan Schreiber, MD, director of the Clinic for Internal Medicine at Kiel Campus of the University Hospital Schleswig-Holstein in Germany, in a statement on the PLANETCD study. “This robust evidence makes a compelling case for the use of biosimilars and will inform decision-making by gastroenterologists when choosing anti-TNF therapy for their patients,” he added.
Hyoung-Ki Kim, vice chairman at Celltrion Healthcare, added, “The PLANETCD study is the first investigation of the therapeutic efficacy of an infliximab biosimilar powered to show noninferiority to reference infliximab in inflammatory bowel disease…[PLANETCD] together with the evidence from the influential NOR-SWITCH study, which was performed across multiple indications, support the equivalence between CT-P13 and reference infliximab.”
Reference
Ye BD, Pesegova M, Alexeeva O, Osipenko M, Lahat A, Dorofeyev A. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study [published online, March 28, 2019]. Lancet. doi: 10.1016/S0140-6736(18)32196-2.
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar and Biologic Use Increasing in Greek Patients With IBD
April 19th 2025A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Early Success of Adalimumab Biosimilars Featured at AMCP 2025
April 5th 2025High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).